Micellar Delivery of Bicalutamide and Embelin for Treating Prostate Cancer
- 466 Downloads
To examine the effect of bicalutamide and embelin on the growth of prostate cancer cells in vitro and in vivo
Cell viability was determined by MTT assay. Micelles were fabricated with polyethylene glycol-b-polylactic acid (PEG-PLA) copolymer and characterized in terms of particle size, micellar solubilization and drug loading, followed by evaluation in nude mice bearing LNCaP xenografts.
Embelin induced caspase 3 and 9 activation in LNCaP and C4–2 cells by decreasing XIAP expression and was more potent than bicalutamide in killing prostate tumor cells irrespective of their androgen status. As analyzed by isobologram analysis the combination of bicalutamide and embelin was synergistic for C4–2 but additive and slightly antagonistic for LNCaP cells. Micellar formulation resulted in at least 60-fold increase in the aqueous solubility of bicalutamide and embelin. Tumor growth was effectively regressed upon treatment with bicalutamide, but the extent of tumor regression was significantly higher when bicalutamide was formulated in micelles. However, tumor response to bicalutamide stopped after prolonged treatment and began to grow. Sequential treatment with XIAP inhibitor embelin resulted in regression of these hormone refractory tumors.
Combined treatment with bicalutamide and embelin may be an effective strategy for treating hormone refractory prostate cancer.
KEY WORDSandrogen bicalutamide embelin micelles prostate cancer
- 2.Huggins C, Hodges CV. Studies on prostatic cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. Cancer Res 1941;1:293–7.Google Scholar
- 7.de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986;135:303–7.PubMedGoogle Scholar
- 8.Blackledge G. Casodex-mechanism of action and opportunity for usage. Cancer 1993;72:3830–3. doi: 10.1002/1097-0142(19931215)72:12+<3830::AID-CNCR2820721713>3.0.CO;2-D.PubMedCrossRefGoogle Scholar
- 18.Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller PP, et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 2004;47:2430–40. doi: 10.1021/jm030420+.PubMedCrossRefGoogle Scholar
- 21.Ahn KS, Sethi G, Aggarwal BB. Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Mol Pharmacol 2007;71:209–19. doi: 10.1124/mol.106.028787.PubMedCrossRefGoogle Scholar
- 39.Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 2005;65:9611–6. doi: 10.1158/0008-5472.CAN-05-0817.PubMedCrossRefGoogle Scholar